David Bredt's most recent trade in Rapport Therapeutics Inc. was a trade of 6,000 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 6,000 | 88,080 | - | - | Stock Options (Right to Buy) | |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 17 Feb 2026 | 6,000 | 393,075 | - | 1.8 | 10,800 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.95 per share. | 17 Feb 2026 | 5,400 | 389,275 | - | 28.9 | 156,328 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.59 per share. | 17 Feb 2026 | 2,200 | 387,075 | - | 29.6 | 65,108 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.02 per share. | 17 Feb 2026 | 900 | 394,675 | - | 28.0 | 25,219 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 103,000 | 103,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 15 Jan 2026 | 8,300 | 395,775 | - | 26.8 | 222,652 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 15 Jan 2026 | 200 | 395,575 | - | 27.4 | 5,480 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 18,000 | 410,642 | - | - | Common Stock | |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 31 Dec 2025 | 6,567 | 404,075 | - | 30.0 | 197,338 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.95 per share. | 15 Dec 2025 | 7,704 | 393,438 | - | 29.9 | 230,711 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.68 per share. | 15 Dec 2025 | 796 | 392,642 | - | 30.7 | 24,419 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.39 per share. | 17 Nov 2025 | 5,344 | 401,142 | - | 25.4 | 135,696 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.84 per share. | 17 Nov 2025 | 3,156 | 406,486 | - | 24.8 | 78,395 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.73 per share. | 15 Oct 2025 | 7,418 | 410,724 | - | 25.7 | 190,887 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.16 per share. | 15 Oct 2025 | 1,082 | 409,642 | - | 26.2 | 28,310 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.88 per share. | 15 Sep 2025 | 5,098 | 421,544 | - | 23.9 | 121,761 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.66 per share. | 15 Sep 2025 | 3,402 | 418,142 | - | 24.7 | 83,888 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.98 per share. | 15 Aug 2025 | 8,300 | 426,842 | - | 15.0 | 124,308 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.79 per share. | 15 Aug 2025 | 200 | 426,642 | - | 15.8 | 3,158 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 15 Jul 2025 | 8,500 | 435,142 | - | 14.0 | 118,962 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 16 Jun 2025 | 8,500 | 443,642 | - | 11.0 | 93,522 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.56 per share. | 15 May 2025 | 8,500 | 452,142 | - | 9.6 | 81,262 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 15 Apr 2025 | 8,500 | 460,642 | - | 9.6 | 81,310 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 14 Mar 2025 | 8,500 | 469,142 | - | 10.8 | 92,205 | Common Stock |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 28,302 | 28,302 | - | - | Stock Option (Right to Buy) |